Filed revenue acceleration
Active · now 18.494783106619582%TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.
Free trial
Analyze this stock with AI
Ask AI to research recent events and build a visual report.
Tell your AI:
“Help me set up FinLab and analyze EXEL Exelixis, Inc.: https://finlab.finance/en/setup?stock=EXEL”
EXEL
Exelixis, Inc. Healthcare As of 2026-06-18
Quality Top tier
Valuation Expensive
Risk Moderate
Active signals Active Filed revenue acceleration
51.91 Close (USD)
+24.87% 60-day
- Quality is top-tier. Operating margin ranks above roughly 89% of the liquid US common-stock universe. TTM ROE is about 43.0%.
- Valuation is expensive. TTM P/E is in the 70th percentile, above most peers.
- Recent volatility is moderate. 60-day annualized volatility is near the 58th percentile. Average 20-day dollar volume is about $126.3M.
- Signals are active now. Filed revenue acceleration currently holds; the tables below show what followed in this stock’s own history.
Factor profile
Factor radar Weak Valuation
39Valuation
Indicators in this group are ranked by market percentile; lower valuation and volatility are better.
TTM P/E 17.19
Price / book 6.93
Free-cash-flow yield (%) 6.86
Historical evidence
Signals active now
Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.
Valuation regime and forward returns
Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.
0-20 Insufficient data
20-40 +19.7% Now
40-60 +2%
60-80 +29.8%
80-100 +29.1%
| PE percentile band | Sample days | 240-day avg return | Median | Win rate | Avg excess (vs index) |
|---|---|---|---|---|---|
| 0-20 | 0 | Insufficient data | |||
| 20-40 You are here | 249 | +19.7% | +23.8% | 81.9% | +13.9% |
| 40-60 | 479 | +2% | -4.8% | 45.1% | -9.9% |
| 60-80 | 328 | +29.8% | +21.4% | 63.7% | +16.6% |
| 80-100 | 187 | +29.1% | +21.2% | 100% | +3.1% |
Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.
Current TTM P/E is about 17.19, placing it in the 25.7 own-history percentile, inside the 20-40 bucket.
Valuation × momentum analogs
Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
Now
Insufficient data
(28d)
(28d)
+5%
463d
+6.7%
306d
60-day momentum down
+13.1%
133d
+3.4%
319d
+32%
114d
Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.
Market-wide momentum baseline
Across 94,737 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.40%, a 58.3% positive-return rate, and +3.10 percentage points of average excess return versus the S&P 500.
Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).
Signals not active now
Inactive signals still show the stock-specific historical forward-return distribution for context.
52-week adjusted-price high
PendingAdjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.
19 times historically; 60-day forward avg +4.07%, win rate 55.6%, beating the market by +0.55 pts on average.
Top-quintile 6-month momentum
PendingThe stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.
22 times historically; 60-day forward avg +8.03%, win rate 54.5%, beating the market by +2.38 pts on average.
EPS surprise beat
PendingReported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.
33 times historically; 60-day forward avg +8.76%, win rate 71%, beating the market by +6.49 pts on average.
Free trial
Analyze this stock with AI
Ask AI to research recent events and build a visual report.
Tell your AI:
“Help me set up FinLab and analyze EXEL Exelixis, Inc.: https://finlab.finance/en/setup?stock=EXEL”
Method and limits
- Returns use us_price:adj_close, adjusted for splits and dividends where available.
- Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
- Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
- The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
- Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
- Overlapping event windows are descriptive distributions, not independent samples.
This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.